Betta Pharmaceuticals Co., Ltd.

Hewlett Packard Enterprise Development LP

Jiabing Wang

Lieming Ding

Yao Zhang

Chao Wang

Xiaofeng Xu

Yiqian Wang

Yan Xu

Wei Wang

Chunhui Zhang

Zhenfan Yang

Hao Wu

Jun Yu

Xiangyong Liu

David Yunzhi Li

Yabin Li

Wei Gu

Bang Fu

Yongxin Ke

Hong Lan

Xintao Zhao

Wenmao Wu

Yifei Shen

Zhongyan Chen

Dongjie Feng

Bo Zhan

Xiaojing Tang

Zhixin Xiong

Wenjun Du

Rongwen Yang

Yuan Lu

Jiangqi He

Boyan Li

Xiaolin Zhang

Qingbei Zeng

Xiao Zhou

Provided herein are compounds of Formula (I), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.

Immunomodulators, compositions and methods thereof

The present invention relates to a salt form of (R)—N-(5-((4-ethylpiperazin-1-yl)methyl)pyridin-2-yl)-5-fluoro-4-(6-fluoro-1-methyl-1,2,3,4-tetrahydrobenzo[4,5]imidazo[1,2-a]pyridin-8-yl)pyrimidin-2-amine (compound I) as shown in structural formula (I) or a crystal form thereof, and also relates to a method for preparing the salt form of compound I and/or the crystal form thereof, a pharmaceutical composition containing the salt form and/or the crystal form, and the use of same in the preparation of drugs for treating diseases, illnesses or conditions, or a method for treating diseases, illnesses or conditions.

Crystal form of compound for inhibiting the activity of CDK4/6 and use thereof

The invention relates to a bromodomain inhibitor. The invention also provides compositions and formulations comprising such compounds, and methods of using and preparing such compounds.

Compound functioning as bromodomain protein inhibitor, and composition

The invention relates to a bromodomain inhibitor. The invention also provides compositions and formulations comprising such compounds, and methods of using and preparing such compounds. 

Disclosed are a compound (as shown in formula I) as an extracellular signal-regulated kinase (ERK) inhibitor, a pharmaceutical composition thereof, a preparation method therefor, and use thereof in treating ERK-mediated diseases. Said compound plays a role by regulating a plurality of processes such as cell proliferation, apoptosis, migration and angiogenesis. 

ERK inhibitor and use thereof

An azatricyclic compound (as represented by Formula I) which acts as an inhibitor of fibroblast growth factor receptors (FGFR), as well as a pharmaceutical composition thereof, a preparation method, and a use therefor in the treatment of FGFR-mediated diseases are provided. The azatricyclic compound exerts an effect by means of participating in the regulation of a plurality of processes such as cell proliferation, apoptosis, migration, neovascularization, and the like. 

FGFR inhibitor and application thereof

The present invention relates to benzimidazole compounds useful in treating for protein kinase-associated disorders. There is also a need for compounds useful in the treatment or prevention of one or more symptoms of cancer, transplant rejections. Furthermore, there is a need for methods for modulating the activity of protein kinases, such as CDK4 and/or CDK6, using the compounds provided herein. 

Benzimidazole derivatives, preparation methods and uses thereof

A network device in a RPR network receives a RPR flooding data packet sent by another network device in the RPR network, determines whether a next-hop network device of the RPR flooding data packet is a source network device sending the RPR flooding data packet, and strips the RPR flooding data packet when determining that the next-hop network device of the RPR flooding data packet is the source network device sending the RPR flooding data packet.

Packet forwarding in RPR network

Growing community of inventors

Beijing, China

Jiabing Wang